IPSEF News and Press, Ipsen

PARIS, FRANCE, 09 March 2026  – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III S...

2026-03-05 14:41:06 ET The last time I spoke about Day One Biopharmaceuticals ( DAWN ), it was regarding a Seeking Alpha article entitled " Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need ." I noted that this company had completed its acquisition o...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alteration i The decision is based on data from the pivotal Phase I...

2026-02-20 14:24:17 ET Shares of Gilead Sciences, Inc. ( GILD ), my favorite in the HIV drugs market, have risen 23.3% since my previous article , " Gilead Sciences: From All-Time Highs To Higher Highs. "... Read the full article on Seeking Alpha For further deta...

2026-02-12 13:52:01 ET More on Genfit, Ipsen S.A. Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript Ipsen S.A. 2025 Q4 - Results - Earnings Call Presentation Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Ipsen S.A....

2026-02-12 11:14:33 ET Ipsen S.A. (IPSEY) Q4 2025 Earnings Call February 12, 2026 8:00 AM EST Company Participants David Loew - MD, CEO & Director Aymeric Le Chatelier - Executive VP & CFO Conference Call Participants Charles Pitman - Barclays B...

2026-02-12 01:25:38 ET More on Ipsen S.A. Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Ipsen rises on FDA breakthrough therapy status for blood cancer therapy Seeking Alpha’s Quant Rating on Ipsen S.A. Histor...

FY 2025 sales growth of 10.9% at CER 1 , or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% 1 ), Rare Disease (102.5% 1 ) and Neuroscience (9.7% 1 ); Somatuline® sales growth of 4.3% 1 , with all other products, excluding Somatuline, achieving double-digit...

PARIS, FRANCE, 29 January 2026  - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position. Peter Guenter holds nearly 40 years of experience as ...

PARIS, FRANCE, 27 January 2026  - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan Murphy, EVP Technical Operations ...